Efavirenz is a non-nucleoside inhibitor used for HIV/AIDS treatment.
- New Study
- Preliminary research suggests it could be repurposed for chikungunya treatment.
- Current Scenario
- No approved antiviral drugs exist for chikungunya, only a few have been tested in animal models.
Chikungunya in India
Chikungunya is a mosquito-borne viral disease characterized by fever and severe joint pain, transmitted by infected mosquitoes like Aedes aegypti and Aedes albopictus.
- Cause:Chikungunya is caused by a virus belonging to the alphavirus genus of the family Togaviridae.
- Re-emergence in 2006 after 20-30 years.
- 2006 Outbreak
- 14 million suspected cases, with 2,001 lab-confirmed cases.
- Decline until 2014, followed by a rise in cases from 2018 onwards.
Study Findings (IIT Roorkee Research)
- Conducted by Department of Biosciences and Bioengineering, IIT Roorkee.
- Published in: ACS Infectious Diseases.
A. In-vitro (Cell Line) Studies
- Tested on Vero cells and human hepatic cell lines (as chikungunya affects liver hepatocytes).
- Results:
- Efavirenz inhibited virus replication by 99% at low micromolar concentrations.
- Drug was effective up to 6-8 hours post-infection, acting in the early replication phase.
B. In-vivo (Mouse Model) Studies
- Efavirenz treatment significantly reduced viral load in chikungunya-infected mice.
- Unexpected Finding:
- Increased swelling in the limbs due to the drug’s pro-inflammatory action.
- Despite this, viral propagation was controlled.
A clean PDF of this page with the C4S header — it opens right away, and the link comes to your WhatsApp too.
C. Supporting Evidence from HIV Patients
Free live session
NABARD Sprint 60: the 2025 cut-offs and your 60-day Phase I plan
8 of the top 10 in NABARD Grade A 2025, Rank 1 included, and Rank 1 back to back before that in 2021 and 2022: all prepared with C4S. The 2025 cycle was the toughest on record at every stage. This session reads those numbers properly and turns them into a 60-day, week-by-week plan for Phase I.
In 3 days · Sun, 18 Oct at 7:30 PM IST · 75 minutes · free
- Anecdotal case of a 43-year-old HIV patient receiving efavirenz showed improvement in chikungunya symptoms.
- Improvement not solely attributed to efavirenz but aligns with anti-chikungunya activity observed in lab studies.
4. Potential and Future Steps
- Efavirenz shows strong promise due to:
- Good pharmacokinetics (effective drug absorption and metabolism).
- Proven safety and efficacy in HIV treatment.
- Demonstrated ability to suppress chikungunya virus replication.
- Next Steps:
- Clinical trials to assess efavirenz’s effectiveness and safety in humans for chikungunya treatment.
Source: TH
